Journal article icon

Journal article

A phase I study of 99mTc-hR3 (DiaCIM), a humanized immunoconjugate directed towards the epidermal growth factor receptor.

Abstract:

A phase I trial was conducted to evaluate the safety, tumour and normal tissue localization, pharmacokinetics and radiation dosimetry of Tc-hR3, a humanized monoclonal antibody directed towards the epidermal growth factor receptor, in 12 patients with recurrent or metastatic epithelial malignancies. Patients were injected intravenously with 3.0 mg or 6.0 mg (1010 MBq) of Tc-hR3. Blood and plasma concentrations of radioactivity were measured and a complete 24 h urine collection was obtained. W...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Oncology
Reilly, RM More by this author
Hendler, A More by this author
Expand authors...
Journal:
Nuclear medicine communications
Volume:
23
Issue:
12
Pages:
1155-1164
Publication date:
2002-12-05
DOI:
EISSN:
1473-5628
ISSN:
0143-3636
URN:
uuid:054a81e4-f7ce-4bef-85f2-b4c3b5e2562d
Source identifiers:
131272
Local pid:
pubs:131272

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP